摘要
目的观察葛根素注射液治疗重度子痫前期患者临床疗效,并探讨其作用机制。方法将100例重度子痫前期患者随机平均分为葛根素辅助治疗组(观察组)和常规治疗组(对照组)各50例。在0天和7天分别测量患者的平均动脉压(MAP)、24小时尿蛋白水平、全血比粘度、红细胞比容(HCT%)、血小板(PLT)和APTT,以及血中ET-1、IL-6和TNF-α水平。结果通过7天的治疗后,两组患者MAP、24小时蛋白尿、全血比粘度、HCT%、PLT均有显著改善,差异有统计学意义(均P<0.05)。同时观察组患者MAP、24小时蛋白尿、全血比粘度、HCT%和PLT改善情况较对照组更加明显,差异有统计学意义(均P<0.05)。常规的治疗不能改善APTT的异常(P>0.05),而观察组患者APTT有明显的延长(P<0.05)。进一步研究发现,治疗7天后两组患者血中ET-1、IL-6和TNF-α水平均较治疗前有不同程度下降,差异有统计学意义(均P<0.05),且观察组患者血中ET-1、IL-6和TNF-α水平下降更加明显,差异有统计学意义(均P<0.05)。治疗过程中未见明显的药物不良反应。结论葛根素注射液可有效改善重度子痫前期的临床症状,并能明显缓解子痫前期患者的凝血功能障碍和血管内皮细胞功能异常,同时治疗过程中未见明显的药物不良反应,值得临床推广应用。
Objective To investigate curative effect and application value of puerarin in the treatment of severe pre- eclampsia. Methods One hundred patients with severe preeclampsia were randomly divided into regular treatment group （control group） and puerarin ＋ regular treatment group （treatment group）. Before and after treatment, mean arterial pressure （MAP）, 24-hours urine protein, whole blood contrast viscosity （WBCV）, HCT %, PLT, APTT and the serum levels of ET-1, IL-6 and TNF-α Results After 7 days treatment, MAP, 24-hours urine protein, whole blood contrast viscosity （WBCV）, HCT %, PLT and the serum levels of ET-1, IL-6 and TNF-α were markedly improved. Moreover, the improvements in treatment group were more significant than in control group. Meanwhile, no difference on APTT time was found before and after treatment in control group. However, APTT was notably increased in treatment group after intervention. Conclusion Puerarin is safe and effective in the treatment of severe preeclampsia.
出处
《西部医学》
2013年第5期693-695,共3页
Medical Journal of West China
关键词
重度子痫前期
葛根素
凝血功能
Severe preeclampsia
Puerarin
Coagulation function
